Compounds > risedronic acid
Page last updated: 2024-08-16

risedronic acid and Inflammatory Bowel Diseases

risedronic acid has been researched along with Inflammatory Bowel Diseases in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bell, A; Brooklyn, TN; Creed, TJ; Fraser, WD; Kriel, MH; Linehan, J; Lockett, M; Probert, CS; Przemioslo, R; Smithson, JE; Tobias, JH1
Colao, A; Doldo, P; Falbo, A; Manguso, F; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tauchmanovà, L; Tolino, A; Zullo, F1
Henderson, S; Hoffman, N; Prince, R1

Trials

3 trial(s) available for risedronic acid and Inflammatory Bowel Diseases

ArticleYear
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:3

    Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Hip Joint; Humans; Inflammatory Bowel Diseases; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prednisolone; Risedronic Acid

2010
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:9

    Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; Inflammatory Bowel Diseases; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risedronic Acid; Spinal Fractures; Treatment Outcome

2005
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:1

    Topics: Absorptiometry, Photon; Adult; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Osteoporosis; Reference Values; Risedronic Acid; Risk Assessment; Treatment Outcome

2006